THE WOODLANDS, Texas,
June 3 /PRNewswire-FirstCall/ --
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a biopharmaceutical
company focused on discovering and developing breakthrough
treatments for human disease, announced today that Alan J. Main,
Ph.D., Lexicon's executive vice president of pharmaceutical
research, will present at two investor conferences next week in
New York. Dr. Main will present at
the 9th Annual Needham Healthcare Conference on Wednesday, June 9, 2010 10
a.m. Eastern Time; and at the Jefferies 2010 Global Life
Sciences Conference on Friday, June 11, 2010 at 11 a.m. Eastern Time. Investors can access
a webcast of the Jefferies Conference presentation at
www.lexpharma.com.
Needham & Company's Annual Healthcare Conference is a forum
for institutional investors and venture capital firms to hear the
latest updates from senior management teams of both public and
private companies in the biotechnology, specialty pharmaceuticals,
medical technology, and diagnostics sectors. The Jefferies
Global Life Sciences Conference will feature presentations from
more than 350 public and private healthcare companies across the
life sciences spectrum, including biotechnology, life science
tools, medical devices, diagnostics, specialty pharmaceutical, and
multi-national pharma.
About Lexicon
Lexicon is a biopharmaceutical company focused on discovering
and developing breakthrough treatments for human disease.
Lexicon currently has four drug candidates in mid-stage
development for diabetes, irritable bowel syndrome, carcinoid
syndrome and rheumatoid arthritis, all of which were discovered by
Lexicon's research team. Lexicon has used its proprietary
gene knockout technology to identify more than 100 promising drug
targets. Lexicon has focused drug discovery efforts on these
biologically-validated targets to create its extensive pipeline of
clinical and preclinical programs. For additional information
about Lexicon and its programs, please visit www.lexpharma.com.
Safe Harbor Statement
This press release contains "forward-looking" statements,
including statements relating to Lexicon's growth and future
operating results, discovery and development of products, strategic
alliances and intellectual property, as well as other matters that
are not historical facts or information. All forward-looking
statements are based on management's current assumptions and
expectations and involve risks, uncertainties and other important
factors, specifically including those relating to Lexicon's ability
to successfully conduct preclinical and clinical development of its
potential drug candidates, advance additional candidates into
preclinical and clinical development, obtain necessary regulatory
approvals, achieve its operational objectives, obtain patent
protection for its discoveries and establish strategic alliances,
as well as additional factors relating to manufacturing,
intellectual property rights, and the therapeutic or commercial
value of its drug candidates, that may cause Lexicon's actual
results to be materially different from any future results
expressed or implied by such forward-looking statements.
Information identifying such important factors is contained under
"Factors Affecting Forward-Looking Statements" and "Risk Factors"
in Lexicon's annual report on Form 10-K for the year ended
December 31, 2009, as filed with the
Securities and Exchange Commission. Lexicon undertakes no
obligation to update or revise any such forward-looking statements,
whether as a result of new information, future events or
otherwise.
SOURCE Lexicon Pharmaceuticals, Inc.